Business Wire

Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium


Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that Maria Escolar, M.D., Chief Medical Officer, will present preliminary clinical data on the treatment of its first patient in the RESKUE Phase 1/2 clinical trial for FBX-101, the Company’s novel gene therapy for the treatment of patients with Krabbe disease. The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Maria Escolar, M.D., Chief Medical Officer at Forge Biologics (Photo: Business Wire)

RESKUE is the first-in-human clinical trial where subjects are administered FBX-101, an Adeno-Associated Virus (AAV) systemic gene replacement strategy, after full myeloablation and umbilical cord blood transplantation. Clinical data support preclinical observations that this approach may lessen many of the immune challenges previously observed with systemic AAV gene delivery and can create a novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to UCBT. The first patient’s data from the RESKUE clinical trial demonstrate that intravenous FBX-101 following UCBT has been safe and well tolerated through Day 180. Notably, the data demonstrate an absence of humoral immune response against the vector and significantly increased GALC enzyme activity. Through Day 180, the patient exhibited improved motor activity and normal brain development compared to previously reported transplanted patients with Krabbe disease.

“Krabbe disease is a rapidly fatal neurodegenerative disorder. While early transplant can help patients, they inevitably develop motor disease. FBX-101, a systemic AAV therapy administered after hematopoietic stem cell transplantation, was well tolerated in the first patient and the initial clinical data support normal brain development during this period of rapid myelination, and normal gross motor function," stated Dr. Escolar. "The increased GALC levels and ablated immune response achieved in this transplant environment may represent a paradigm shift in the treatment of patients with Krabbe disease and for the field of gene therapy. We are excited by results thus far and we look forward to continuing this trial.”

“We are thrilled with Forge’s commitment to get this much-needed therapy into a clinical trial,” said Stacy Pike-Langenfeld, Co-Founder and President of KrabbeConnect.

“We're deeply grateful for this progress toward better treatments for patients suffering from Krabbe disease thanks to the dedication of the team at Forge,” said Anna Grantham, Leukodystrophy Care Network Director of Hunter’s Hope Foundation.

Dr. Escolar’s poster, “Intravenous FBX-101 (AAVrh10.hGALC) following hematopoietic stem cell transplantation increases GALC activity, improves gross motor function, and maintains brain development in Krabbe patients in the RESKUE Phase 1/2 Clinical Trial,” will be available virtually for all symposium attendees and displayed in the main poster hall throughout the course of the conference. The poster walk will take place on Wednesday, August 31, 2022, from 18:45-20:15 CET. For more details on the symposium, please visit:

About Krabbe Disease

Krabbe disease is a rare, neurodegenerative disease affecting about 1-2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactocerebrosidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells and loss of motor function. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing and cognitive problems, and vision and hearing loss. Early onset or “Infantile” Krabbe disease cases usually results in death of patients by the age of two years, while later onset or “Late Infantile” patients usually die by the age of six. Although bone marrow transplant is the current standard of care for treating the central nervous system in patients with Krabbe disease, patients continue to develop peripheral nervous system disease that eventually results in death. Currently, 10 states in the USA are approved to try and identify babies with Krabbe disease as part of newborn screening programs.

About FBX-101

Forge developed FBX-101 to treat patients with Infantile Krabbe disease. FBX-101 is an adeno-associated viral serotype rh10 (AAVrh10) gene therapy that is typically delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease, as well as to drastically improve lifespan in animal models of the disease. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies and extend the duration of gene transfer.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications

Families and Clinician Inquiries
Maria Escolar, M.D.
Chief Medical Officer

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations

Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mary Kay Awards Education Grant to Young Woman Aspiring to Become First Latin American Woman Astronaut to Visit Mars5.10.2022 23:40:00 CEST | Press release

As a decades-long leader in women’s empowerment and innovative science, Mary Kay celebrates young women who are taking charge of their futures through leadership, innovation, and determination to excel in STEAM fields. Women make up only 28% of the workforce in science, technology, engineering, and math. [1] By offering continued support to young women in STEAM fields, they are continuing Mary Kay’s mission, which is to improve women's lives everywhere. This press release features multimedia. View the full release here: Mary Kay is committed to inspiring young women making tremendous contributions to STEAM fields to continue to pursue their dream. (Photo: Mary Kay Inc.) “More young women gaining access to STEAM education leads to an increase in women embracing careers in those fields. In turn, this provides access to more equal opportunities for women, narrows the gender pay gap, bolsters economies, and eliminates bias in scient

300 Rimini Street Employees Will Gather in Las Vegas to Handmake 500 Fleece Blankets for Local Foster Children, Shelter Pets, and Homeless Youth5.10.2022 23:09:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that on October 6, 2022, over 300 Rimini Street employees gathered in Las Vegas will handmake 500 fleece blankets for local foster children. The blankets will then be donated to Clark County (Nev.) Department of Family Services and Foster Kinship, a Las Vegas-based non-profit. The volunteers will also craft 100 smaller blankets to be donated to the Las Vegas SPCA for animals waiting for their forever homes. The remaining fabric will be donated to volunteer quilters who sew garments for local homeless youth. The 500 blankets will be part of the supply package for recently appointed guardians to gift to the child upon arrival, helping them feel welcome during their critical adjustment phase. The fleece fabric used for the blankets is adorned with children’s characters and

Pyramid Analytics Formalizes US Federal Business Practice5.10.2022 21:04:00 CEST | Press release

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced a new business practice dedicated to the specific needs of U.S. federal agencies. Led by a team of experts with a deep background in the federal market segment, Pyramid’s Federal Business Practice builds on the company’s success with federal agencies such as the U.S. Department of Veterans Affairs (VA) and strengthens its focus and commitment to providing the U.S. Federal Government and federal partners with sales, technical expertise, and services to deploy Decision Intelligence for strategic uses at scale. Key Points: Decision Intelligence enabled by AI and Machine Learning (ML) can modernize the delivery of critical public services, including healthcare, homeland security, and defense in the US federal market segment. President Biden’s Fiscal Year (FY) 2023 Budget proposes spending $65 billion on IT for civilian federal agencies and prioritizes IT Modernization, Cybersecurity, and Digi

Brijesh Jeevarathnam to Succeed Kelly Meldrum as Global Head of Fund Investments at Adams Street Partners5.10.2022 15:00:00 CEST | Press release

Adams Street Partners, LLC, a private markets investment firm with more than $50 billion of assets under management, announced today that Brijesh Jeevarathnam will be promoted to Partner & Global Head of Fund Investments. Jeevarathnam, who joined Adams Street as a Partner in Primary Investments in 2016, will also become a member of the firm’s Executive Committee as part of his new role. This press release features multimedia. View the full release here: Brijesh Jeevarathnam has been promoted to Partner & Global Head of Fund Investments of Adams Street Partners. (Photo: Business Wire) Jeevarathnam succeeds Kelly Meldrum, who is retiring after 17 years as a Partner & Head of Primary Investments at the firm. Meldrum will transition her duties at year-end and will make herself available through the end of Q1 2023. “Over her long tenure with Adams Street, Kelly has made innumerable contributions to the firm, not the least of which wa

NetWitness Launches White Hat Wednesdays Conversation Series5.10.2022 15:00:00 CEST | Press release

NetWitness: DATE & LOCATION: To register, visit the White Hat Wednesdays link here. Wednesday, October 19 at 11:30am ET Wednesday, November 16 at 11:30am ET More dates to be announced WHAT: NetWitness will be launching White Hat Wednesdays, a series of discussions exploring the latest cybersecurity threats enterprises face today, with the first session kicking off on October 19. Cybersecurity experts will share their personal experience regarding the evolution of today’s attacks and the steps incident response teams are taking to detect, mitigate, assess, and remedy these situations. The first topic will focus on threats to the financial industry and FIN13, a threat actor that targets this vertical. The discussion will include how these types of groups operate as well as what an attack on financial technology looks like. WHO: The following spokespeople and executives will be leading the discussions: Stefano Maccaglia, Practice Manager, NetWitness Incident Response Will Gragido, Head of